CLINICAL GUIDE | UPDATED MAY 2026
One of the most persistent HRT breast cancer myths concerns whether hormone replacement therapy causes breast cancer. This misconception has prevented countless women from accessing effective menopause treatment. Let’s examine the actual HRT breast cancer risk based on current medical evidence and put these concerns into proper perspective.
Understanding How HRT Works
As we age, our bodies naturally produce less of several key hormones, including oestrogen, progestogen, and testosterone. This hormonal decline leads to symptoms such as hot flushes, reduced libido, and other menopause-related changes. The primary purpose of HRT is to replace oestrogen to help relieve menopausal symptoms, whilst some women may also be prescribed a small amount of testosterone to support sex drive.
There are two main forms of HRT:
- Combined HRT: Contains both oestrogen and progestogen, typically prescribed for women who still have their womb
- Oestrogen-only HRT: Usually prescribed for women who have had a hysterectomy (womb removal)
Additionally, vaginal oestrogen treatments target specific vaginal and bladder symptoms such as dryness, soreness, and irritation.
The Real HRT Breast Cancer Risk Percentage
Combined HRT and Breast Cancer Risk
For women taking combined HRT, there is a potentially slight increase in breast cancer risk, but the overall risk remains low. Importantly, with modern bioidentical progesterone that more closely mimics the body’s natural hormone, the risk of breast cancer is not increased during the first five years of use.
To put the HRT breast cancer risk percentage into perspective, lifestyle factors in your 50s pose greater risks:
- Being overweight increases breast cancer risk more than HRT
- Drinking two or more units of alcohol daily carries higher risk than HRT
- These HRT cancer risk factors help contextualise the actual threat level
Does Estrogen-Only HRT Increase Breast Cancer Risk?
For women using oestrogen-only HRT after a hysterectomy, there is little to no increased breast cancer risk. This represents a significant difference from combined therapy and helps explain why treatment recommendations vary based on individual circumstances.
Why Progestogen Matters: Menopause HRT Safety Considerations
You might wonder why progestogen is included if it potentially increases risk. The answer lies in comprehensive menopause HRT safety:
If you still have your womb and take oestrogen-only HRT, the womb lining can thicken, significantly increasing the risk of endometrial (womb) cancer. Progestogen is prescribed alongside oestrogen specifically to protect the womb lining and reduce this cancer risk.
This explains the careful balance clinicians must strike when prescribing hormone replacement therapy to ensure overall safety.
Vaginal Oestrogen Safety Profile
Vaginal oestrogen safety differs considerably from systemic HRT. When using vaginal oestrogen in the form of pessaries, cream, or gel applied inside the vagina, you typically don’t need progestogen. This is because only minimal amounts of oestrogen are absorbed systemically, meaning cancer risk doesn’t increase.
However, if you use transdermal oestrogen gel through the skin (such as Oestrogel or Sandrena), more oestrogen enters your bloodstream. Therefore, if you still have a womb, progestogen is also needed to maintain safety.
HRT and Breast Cancer Risk: A Realistic Perspective
Understanding HRT and breast cancer risk in 2024 requires considering the complete picture:
- Individual risk assessment varies significantly between women
- Duration of treatment affects risk calculations
- Type of HRT (combined vs oestrogen-only) influences outcomes
- Delivery method (oral, transdermal, vaginal) impacts absorption
- Personal medical history and family history matter
The relationship between pregnancy and HRT also influences breast cancer risk, as pregnancy typically provides protective effects that must be weighed against treatment benefits.
Making Informed Decisions About HRT
Given the complexity of progestogen breast cancer interactions and individual risk factors, it’s essential to consult with a menopause specialist. They can provide personalised advice based on:
- Your specific symptoms and medical history
- Current research on HRT and breast cancer risk
- Your individual risk-benefit profile
- Alternative treatment options if appropriate
Conclusion
The HRT breast cancer myth that hormone replacement therapy inevitably causes cancer is not supported by current evidence. Whilst combined HRT breast cancer risk may be slightly elevated, this must be balanced against the significant benefits HRT provides and compared to other modifiable risk factors.
Understanding the nuanced relationship between hormone replacement therapy cancer risk helps women make informed decisions about their menopause treatment, rather than avoiding potentially beneficial therapy based on outdated fears.
